PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
Rhea-AI Summary
PROCEPT BioRobotics (Nasdaq: PRCT) announced that members of its management team will present and host investor meetings at the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026. Investors can view the presentation or request meetings through their Baird representative.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 04 | 2Q26 earnings report | Positive | +5.8% | Revenue growth, reiterated guidance, and improved gross margin accompanied quarterly results. |
| Jul 14 | Earnings date notice | Neutral | -0.8% | The company scheduled release of second-quarter financial results and its conference call. |
| May 28 | Clinical enrollment milestone | Positive | +2.8% | WATER IV RP enrollment was completed and expanded FDA IDE approval was announced. |
| May 14 | Guideline recommendation update | Positive | +2.6% | Updated AUA guidelines strengthened recommendations for Aquablation therapy. |
| Apr 30 | Investor conference schedule | Neutral | +2.5% | Management announced participation in three upcoming investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operating, clinical, and guideline announcements were followed by positive reactions, while scheduling notices showed mixed reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will present and host investor meetings at the upcoming Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15.
To view the presentation or schedule a meeting with management, please reach out to your Baird representative.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. In addition to its leadership in BPH treatment, the Company is pursuing clinical research initiatives in prostate cancer utilizing investigational applications of its robotic and AI-enabled technologies. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Investor Contact:
Marissa Bych
Managing Director
Gilmartin Group LLC
Marissa@gilmartinir.com
